Clinical Trial Update: Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of gemcitabine plus bevacizumab for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)

Snippet

Sponsor: Emory University | Conditions: Fallopian Tube Neoplasms, Ovarian Cancer | Phase 2 | Status: WITHDRAWN